Rocket Pharmaceuticals, Inc.

RCKT · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.2%

Institutions91.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$0	$0	$0	$0	$0	$0	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$231.75M	-$273.20M	-$224.34M	-$167.25M	-$134.30M	-$76.15M	-$71.16M	-$26.74M	-$41.88M	-$20.40M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$223.12M	-$258.75M	-$221.86M	-$169.07M	-$139.70M	-$77.27M	-$74.52M	-$29.50M	-$42.85M	-$67.98M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.01	$-2.73	$-3.26	$-2.67	$-2.52	$-1.00	$-1.00	$-4.00	$-1.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.01	$-2.73	$-3.26	$-2.67	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$77.56M	$163.63M	$140.52M	$232.69M	$297.10M	$185.38M	$111.36M	$78.72M	$29.80M	$80.04M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$330.45M	$527.70M	$551.81M	$497.02M	$590.82M	$372.12M	$251.31M	$101.78M	$129.65M	$113.32M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	$0	$4.88M	–	–	–	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$53.23M	$64.47M	$62.12M	$42.30M	$87.31M	$64.82M	$57.28M	$54.01M	$56.48M	$4.51M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$277.22M	$463.23M	$489.69M	$454.72M	$503.52M	$307.30M	$194.04M	$47.76M	$73.17M	$108.81M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$190.01M	-$209.72M	-$178.14M	-$121.16M	-$74.64M	-$64.66M	-$53.79M	-$26.11M	-$37.27M	-$17.42M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$440000	$5.86M	$8.36M	$7.62M	$20.61M	$23.27M	$1.45M	$70000	$487000	$412000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$190.45M	-$215.59M	-$186.50M	-$128.78M	-$95.25M	-$87.93M	-$55.24M	-$26.18M	-$37.75M	-$17.83M

	You	Peer avg
Revenue Growth	–	+85.2%
ROE	-4.8%	-40.6%

Rocket Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison